Search alternatives:
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
auc larger » much larger (Expand Search)
i cases » _ cases (Expand Search), 8 cases (Expand Search), 1 cases (Expand Search)
3 cases » _ cases (Expand Search), 19 cases (Expand Search)
a large » _ large (Expand Search)
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
auc larger » much larger (Expand Search)
i cases » _ cases (Expand Search), 8 cases (Expand Search), 1 cases (Expand Search)
3 cases » _ cases (Expand Search), 19 cases (Expand Search)
a large » _ large (Expand Search)
-
141
-
142
-
143
-
144
Data_Sheet_3_Carnivores and Communities: A Case Study of Human-Carnivore Conflict Mitigation in Southwestern Alberta.pdf
Published 2020“…<p>Facilitating long-term coexistence between people and large carnivores is a persistent, global conservation challenge. …”
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
Base-case analysis.
Published 2023“…For 10,517,942 individuals born between 2011 and 2021, HTLV-1 antenatal screening costs US$785 million, increases19,586 QALYs and 631 LYs, and prevents 125,421 HTLV-1 carriers, 4,405 ATL cases, 3,035 ATL-associated deaths, 67 HAM/TSP cases, and 60 HAM/TSP-associated deaths, compared with no screening over a lifetime.…”
-
157
-
158
-
159
Image3_Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: first three case reports.jpeg
Published 2023“…</p>Study design<p>The inclusion criteria were left ventricular ejection fraction of 35% or less; heart failure symptoms of New York Heart Association class III or higher despite existing therapies such as revascularization; and a 1-year observation period that included a 3-month immunosuppressive drug administration period after transplantation of iPS cell-derived cardiomyocyte patches to evaluate adverse events, cardiac function, myocardial blood flow, heart failure symptoms, and immune response.…”
-
160